The Associated Press @AP
Chinese health care authorities declined to include Pfizer's COVID-19 treatment drug in a national reimbursement list that would have allowed patients to get it at a cheaper price throughout the country, saying it was too expensive. https://t.co/bNthV6VODt — PolitiTweet.org